Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be
considered exclusive of other methods of care reasonably directed at obtaining the same results. e
ultimate judgment concerning the propriety of any course of conduct must be made by the clinician
aer consideration of each individual patient situation. Neither IGC, the American College of
Rheumatology, nor the authors endorse any product or service associated with the distributor of this
clinical reference tool.
Abbreviations
6MWD, 6-minute walking distance; AHSCT, autologous hematopoetic stem cell transplant;
CCP, cyclic citrullinated peptide; CNI, calcineurin inhibitor; CT, computed tomography; GCs,
glucocorticoids; HRCT, high-resolution computed tomography; IIM, idiopathic inflammatory
myositis (including polymyositis, dermatomyositis, antisynthetase syndrome, immune-mediated
necrotizing myopathy); ILD, interstitial lung disease; IV, intravenous; IVIG, intravenous immune
globulin; JAKi, janus kinase inhibitor; MCTD, mixed connective tissue disease; MDA-5,
melanoma differentiation-associated protein 5; PFT, pulmonary function test; RA, rheumatoid
arthritis; RP-ILD, rapidly progressive ILD; SARD, systemic autoimmune rheumatic disease; SjD,
Sjögren's Disease; SSc, systemic sclerosis; TNFi, tumor necrosis factor inhibitor
e guidelines provide evidence-based recommendations that have been developed using
GR ADE (Grading of Recommendations Assessment, Development, and Evaluation)
methodolog y. GR ADE involves structured literature review, systematic reviews and meta-
analyses of combined data, and expert discussion to assess the certainty in the evidence and
determine the strength of each recommendation.
Source
Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, Khanna D, Guyatt
G, Mirza RD, Aggarwal R, Allen A, Assassi S, Buckley L, Chami H, Corwin DS, Dellaripa
PF, Domsic RT, Doyle TJ, Falardeau CM, Frech TM, Gibbons FK, Hinchcliff M, Johnson
C, Kanne JP, Kim JS, Lim SY, Matson S, McMahan ZH, Merck SJ, Nesbitt K, Scholand MB,
Shapiro L, Sharkey CD, Summer R, Varga J, Warrier A, Agarwal SK, Antin-Ozerkis D, Bemiss
B, Chowdhary V, Dematte D'Amico JE, Hallowell R, Hinze AM, Injean PA, Jiwrajka N, Joerns
EK, Lee JS, Makol A, McDermott GC, Natalini JG, Oldham JM, Saygin D, Showalter Lakin
K, Singh N, Solomon JJ, Sparks JA, Turgunbaev M, Vaseer S, Turner A, Uhl S, Ivlev I. 2023
American College of Rheumatolog y (ACR)/American College of Chest Physicians (CHEST)
guideline for the screening and monitoring of interstitial lung disease in people with systemic
autoimmune rheumatic diseases. Arthritis Rheumatol. 2024 July 08. doi: 10.1002/art.42860.
Online ahead of print.
is article is published simultaneously in Arthritis Care Res. doi: 10.1002/acr.25347.
Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatolog y (ACR)/
American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung
disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol.
doi: 10.1002/art.42861. Online ahead of print.
is article is published simultaneously in Arthritis Care Res. 2024 July 08. doi: 10.1002/
acr.25348.
Mirza R, Bolster MB, Johnson SR, Allen A, Bernstein EJ, Chung JH, Danoff SK, Falardeau
CM, Guyatt G, Ivlev I, Khanna D, Nesbitt K, Parker R, Turner A, Uhl S, George MD. Assessing
Patient Values and Preferences to Inform the 2023 American College of Rheumatolog y/
American College of Chest Physicians Interstitial Lung Disease Guidelines. Arthritis Care Res.
2024 July 08. doi: 10.1002/acr.25346. Online ahead of print.
1258 Upsala Rd
Sanford, FL 32771
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2024 All rights reserved
ACRILD05243
